Search Results
10
Everything
Search Filters
Organization
Eterna Therapeutics
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
February 26, 2025 08:30 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today...
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
January 28, 2025 08:30 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome...
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
January 14, 2025 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101.
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
January 09, 2025 07:30 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of...
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
December 03, 2024 08:30 ET
|
Eterna Therapeutics
Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
November 25, 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Announces $1 Million Stock Repurchase Program
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
November 14, 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
October 30, 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
October 17, 2024 08:00 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
May 10, 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line